$MCK

Rodgers Thomas L sold $514K of MCK

Rodgers Thomas L (EVP, Chief Strategy & BDO) sold 699 shares of MCKESSON CORP (MCK) at $735.27 ($0.51M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodgers Thomas L
Published Jun 3, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 3:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

This disclosure updates the insider-trading tape for MCK but does not introduce new company fundamentals in the article.

02

Market read

A routine insider sale with 10b5-1 reduces fundamental read-through; any price effect is likely limited and short-lived.

03

What to watch

Traders may overreact to single Form 4 prints; the more relevant signal would be a pattern of consecutive sales or changes in plan size/pace.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-06-03) disclosing a sale executed 2026-06-02

Background

SEC Form 4 reports insider transactions; a 10b5-1 plan means trades were scheduled in advance and are often less informative about near-term views.

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson EVP Chief Strategy sold 699 shares (~$514K) in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and should fade unless follow-on selling accelerates.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 plan, reducing the signal of new negative information.

Market effects

Minimal; this is company-specific insider activity with no stated operational or regulatory trigger.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect diversification/tax planning rather than bearish expectations.

Key entities

  • McKesson

    Subject of the Form 4 insider sale by an EVP under a pre-arranged 10b5-1 plan.

  • Rodgers Thomas L

    EVP, Chief Strategy & BDO who sold 699 shares at $735.27 on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.